NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma-Reference-Cited by-同舟云学术

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma

Published:2019-06-26 Issue:9 Volume:8 Page:e1625688
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Singh Vijay Kumar¹,Werner Sebastian¹,Schwalm Simone¹,Lennerz Volker²,Ruf Stephanie¹,Stadler Serena¹,Hackstein Holger³,Reiter Alfred¹,Wölfel Thomas²,Damm-Welk Christine¹,Woessmann Wilhelm¹

Affiliation:

1. Department of Pediatric Hematology and Oncology, Justus-Liebig-University, Giessen, Germany

2. Department of Internal Medicine III, University Medical Center, Johannes Gutenberg University, Mainz, Germany

3. Department of Transfusion Medicine and Haemostaseology, University Hospital Erlangen, Erlangen, Germany

Funder

Von-Behring-Röntgen-Stiftung

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://tandfonline.com/doi/pdf/10.1080/2162402X.2019.1625688

Reference59 articles.

1. The anaplastic lymphoma kinase in the pathogenesis of cancer

2. Distribution ofNPM1-ALKandX-ALKfusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation

3. Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group

4. Advanced stage anaplastic large cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: A report from the children's oncology group

5. Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Scientific Rationale for Targeting Tumor‐Associated Antigens;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

2. ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer;Nature Cancer;2023-07-10

3. Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer—current status and future directions;Translational Lung Cancer Research;2023-02

4. Anaplastic lymphoma kinase-special immunity and immunotherapy;Frontiers in Immunology;2022-07-25

5. NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target;Cancers;2021-01-05